Administration of antithrombin concentrate in infants and children on extracorporeal life support improves anticoagulation efficacy

ASAIO Journal

Volumn 60, Issue 5, 2014, Pages 559-563

  Ryerson, Lindsay M ^a   Bruce, Aisha K ^a   Lequier, Laurance ^a   Kuhle, Stefan ^b   Massicotte, M Patti ^a   Bauman, Mary E ^a  

^a STOLLERY CHILDREN S HOSPITAL   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Anticoagulation; Antithrombin; Children; Extracorporeal life support; Unfractionated heparin

Indexed keywords

DRUG PRODUCTS;

ANTI-COAGULATION; ANTITHROMBIN; CHILDREN; EXTRACORPOREAL LIFE SUPPORTS; UNFRACTIONATED HEPARINS;

POLYSACCHARIDES;

ANTITHROMBIN; HEPARIN; RECOMBINANT ANTITHROMBIN III; ANTITHROMBIN III; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CANADA; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MEGADOSE; EXTRACORPOREAL LIFE SUPPORT; EXTRACORPOREAL OXYGENATION; HUMAN; INCIDENCE; INFANT; MEDICAL RECORD REVIEW; PEDIATRIC ADVANCED LIFE SUPPORT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; ADVERSE EFFECTS; FEMALE; HEART ASSIST DEVICE; MALE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; THROMBOSIS;

ANTITHROMBIN III; CHILD, PRESCHOOL; EXTRACORPOREAL MEMBRANE OXYGENATION; FEMALE; FIBRINOLYTIC AGENTS; HEART-ASSIST DEVICES; HEPARIN; HUMANS; INFANT; MALE; RETROSPECTIVE STUDIES; THROMBOSIS;

EID: 84907018142     PISSN: 10582916     EISSN: 1538943X     Source Type: Journal    
DOI: 10.1097/MAT.0000000000000099     Document Type: Article

References (34)

1. Hirsh J, Warkentin TE, Shaughnessy SG, et al: Heparin and lowmolecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 119 (1 suppl): 64S-94S, 2001.
2. Abildgaard U: Binding of thrombin to antithrombin III. Scand J Clin Lab Invest 24: 23-27, 1969.
3. Rosenberg RD, Damus PS: The purification and mechanism of action of human antithrombin-heparin cofactor. J Biol Chem 248: 6490-6505, 1973.
4. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI; American College of Chest Physicians: Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (6 suppl): 141S-159S, 2008.
5. Andrew M, Paes B, Milner R, et al: Development of the human coagulation system in the full-term infant. Blood 70: 165-172, 1987.
6. Rosenberg RD: Actions and interactions of antithrombin and heparin. N Engl J Med 292: 146-151, 1975.
7. Andrew M, Paes B, Milner R, et al: Development of the human coagulation system in the healthy premature infant. Blood 72: 1651-1657, 1988.
8. Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L: Maturation of the hemostatic system during childhood. Blood 80: 1998-2005, 1992.
9. Andrew M, Marzinotto V, Massicotte P, et al: Heparin therapy in pediatric patients: A prospective cohort study. Pediatr Res 35: 78-83, 1994.
10. Andrew M, Brooker L, Mitchell L: Acquired antithrombin III deficiency secondary to asparaginase therapy in childhood acute lymphoblastic leukaemia. Blood Coagul Fibrinolysis 5 (suppl 1): S24-S36, 1994.
11. Andrew M, Massicotte-Nolan P, Mitchell L, Cassidy K: Dysfunctional antithrombin III in sick premature infants. Pediatr Res 19: 237-239, 1985.
12. Monagle P, Massicotte P: Developmental haemostasis: Secondary haemostasis. Semin Fetal Neonatal Med 16: 294-300, 2011.
13. th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 suppl): e737S-e801S, 2012.
14. Mitchell LG, Goldenberg NA, Male C, Kenet G, Monagle P, Nowak-Göttl U; Perinatal and Paediatric Haemostasis Subcommittee of the SSC of the ISTH: Definition of clinical efficacy and safety outcomes for clinical trials in deep venous thrombosis and pulmonary embolism in children. J Thromb Haemost 9: 1856-1858, 2011.
15. EB H, PK S, CR W: Within-cluster resampling. Biometrika 88: 1121-1134, 2001.
16. Wong TE, Huang YS, Weiser J, Brogan TV, Shah SS, Witmer CM: Antithrombin concentrate use in children: A multicenter cohort study. J Pediatr 163: 1329-34.e1, 2013.
17. Herbert JM, Hérault JP, Bernat A, et al: Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 91: 4197-4205, 1998.
18. Andersson LO, Barrowcliffe TW, Holmer E, Johnson EA, Sims GE: Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration. Thromb Res 9: 575-583, 1976.
19. Sobel M, Fish WR, Toma N, et al: Heparin modulates integrin function in human platelets. J Vasc Surg 33: 587-594, 2001.
20. Y agi M, Murray J, Strand K, et al: Heparin modulates the conformation and signaling of platelet integrin αIibβ3. Thromb Res 129: 743-749, 2012.
21. Xiao Z, Théroux P: Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a lowmolecular-weight heparin and with a direct thrombin inhibitor. Circulation 97: 251-256, 1998.
22. Aggarwal A, Whitaker DA, Rimmer JM, et al: Attenuation of platelet reactivity by enoxaparin compared with unfractionated heparin in patients undergoing haemodialysis. Nephrol Dial Transplant 19: 1559-1563, 2004.
23. Rauova L, Zhai L, Kowalska MA, Arepally GM, Cines DB, Poncz M: Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: Diagnostic and therapeutic implications. Blood 107: 2346-2353, 2006.
24. Agati S, Ciccarello G, Salvo D, Turla G, Undar A, Mignosa C: Use of a novel anticoagulation strategy during ECMO in a pediatric population: Single-center experience. ASAIO J 52: 513-516, 2006.
25. Urlesberger B, Zobel G, Zenz W, et al: Activation of the clotting system during extracorporeal membrane oxygenation in term newborn infants. J Pediatr 129: 264-268, 1996.
26. N iebler RA, Christensen M, Berens R, Wellner H, Mikhailov T, Tweddell JS: Antithrombin replacement during extracorporeal membrane oxygenation. Artif Organs 35: 1024-1028, 2011.
27. Kozul C, Newall F, Monagle P, Mertyn E, Ignjatovic V: A clinical audit of antithrombin concentrate use in a tertiary paediatric centre. J Paediatr Child Health 48: 681-684, 2012.
28. Kuhle S, Eulmesekian P, Kavanagh B, et al: Lack of correlation between heparin dose and standard clinical monitoring tests in treatment with unfractionated heparin in critically ill children. Haematologica 92: 554-557, 2007.
29. Ignjatovic V, Furmedge J, Newall F, et al: Age-related differences in heparin response. Thromb Res 118: 741-745, 2006.
30. Karlaftis V, Attard C, Monagle P, Ignjatovic V: Latent antithrombin levels in children and adults. Thromb Res 131: 105-106, 2013.
31. Prox D, Becker C, Pirie-Shepherd SR, Celik I, Folkman J, Kisker O: Treatment of human pancreatic cancer in mice with angiogenic inhibitors. World J Surg 27: 405-411, 2003.
32. O'Reilly MS: Antiangiogenic antithrombin. Semin Thromb Hemost 33: 660-666, 2007.
33. Salvatierra A, Guerrero R, Rodriguez M, et al: Antithrombin III prevents early pulmonary dysfunction after lung transplantation in the dog. Circulation 104: 2975-2980, 2001.
34. Jormalainen M, Vento AE, Wartiovaara-Kautto U, et al: Antithrombin reduces pulmonary hypertension during reperfusion after cardiopulmonary bypass in a pig. Acta Anaesthesiol Scand 51: 178-188, 2007.